Target Review Group: Toxinology Researchers and Pharmaceutical Development Executives
Abstract:
This profile details the life and work of Timothy Friede, an American layman who achieved acquired broad-spectrum resistance to numerous snake venoms through chronic, intentional self-exposure (over 800 injections and approximately 200 bites) spanning nearly two decades. This self-immunization program, intensified following a near-fatal 2001 monocled cobra bite, produced unique human antibodies of high therapeutic value. In 2017, Friede collaborated with immunologist Jacob Glanville, resulting in the isolation of these broadly neutralizing antibodies. A subsequent 2025 study published in Cell reported that a prophylactic cocktail incorporating two of these antibodies and the anti-inflammatory drug varespladib demonstrated efficacy against 13 of 19 tested venoms, with partial efficacy against the remainder. Critically, the treatment does not provide resistance against viper venom mechanisms (which primarily target tissues and the cardiovascular system). Friede now functions as the Director of Herpetology at Glanville's biotechnology company, Centivax, signaling a shift toward commercial development of a generalized antivenom platform.
Timothy Friede: A Case Study in Acquired Venom Resistance and Antibody Development
c. 1968 Background: Timothy Friede was born around 1968 and worked primarily as a mechanic and in construction prior to his collaboration with biotechnology researchers.
2000 Self-Inoculation Initiation: Friede began injecting himself with small amounts of snake venom after taking a venom extraction class and acquiring a copperhead.
September 12, 2001 Critical Incident: Friede was bitten consecutively by an Egyptian cobra and a monocled cobra. Although prior injections mitigated the Egyptian cobra bite, the monocled cobra bite resulted in temporary paralysis and a four-day coma, requiring external antivenom treatment.
Post-Incident Immunization Strategy: Following the near-fatal incident, Friede systematized his self-immunization process, using standard immunology textbooks (e.g., Stanley Plotkin’s Vaccines) to guide carefully measured and timed venom doses, despite frequent resulting side effects (anaphylactic shocks, blackouts).
Quantitative Exposure: Over 18 years, Friede performed over 800 venom injections and received approximately 200 snake bites from various deadly species, including mambas and taipans.
2017 Scientific Engagement: Immunologist and antivenom researcher Jacob Glanville contacted Friede after learning of his activities via media reports. Friede agreed to supply blood samples for antibody isolation, stipulating an equal profit split from any resultant antivenom.
2018 Cessation of Exposure: Friede received his last intentional bite (from a water cobra) in November 2018 and subsequently ceased the self-immunization practice.
2025 Therapeutic Validation: A 2025 study in Cell by Glanville and colleagues confirmed the efficacy of a cocktail derived from Friede’s immunity. The therapy, combining two neutralizing human antibodies and the anti-inflammatory agent varespladib, counteracted 13 of 19 snake venoms tested, with partial efficacy against the remaining six.
Therapeutic Limitation: The developed antibody cocktail does not confer resistance to viper venom, which utilizes a distinct toxic mechanism (attacking tissues and the cardiovascular system) compared to the venoms targeted.
Current Professional Role: Friede currently holds the title of Director of Herpetology at Centivax, Glanville’s California-based biotechnology company.